Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Phreesia Inc is a health information services business based in the US. Phreesia shares (PHR) are listed on the NYSE and all prices are listed in US Dollars. Phreesia employs 827 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $28.93 |
|---|---|
| 52-week range | $28.34 - $81.59 |
| 50-day moving average | $48.94 |
| 200-day moving average | $57.91 |
| Wall St. target price | $59.23 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-1.64 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $28.93 from 2022-01-26
| 1 week (2022-01-20) | -6.68% |
|---|---|
| 1 month (2021-12-27) | -35.37% |
| 3 months (2021-10-27) | -56.46% |
| 6 months (2021-07-27) | -56.92% |
| 1 year (2021-01-27) | -54.58% |
|---|---|
| 2 years (2020-01-27) | -1.13% |
| 3 years (2019-01-23) | N/A |
| 5 years (2017-01-23) | N/A |
| Revenue TTM | $197 million |
|---|---|
| Gross profit TTM | $96.3 million |
| Return on assets TTM | -11.26% |
| Return on equity TTM | -21.94% |
| Profit margin | -40.51% |
| Book value | $8.96 |
| Market capitalisation | $1.6 billion |
TTM: trailing 12 months
We're not expecting Phreesia to pay a dividend over the next 12 months.
Over the last 12 months, Phreesia's shares have ranged in value from as little as $28.34 up to $81.592. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Phreesia's is 1.2711. This would suggest that Phreesia's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. Its Phreesia Platform offers a suite of solutions to manage the patient intake process, as well as an integrated payments solution for processing of patient payments. The company deploys its platform in a range of modalities, such as Phreesia Mobile, a patients' mobile device; Phreesia Dashboard, a Web-based dashboard for providers; PhreesiaPads, which are self-service intake tablets; and Arrivals Kiosks that are on-site kiosks. Its Phreesia Platform also provides a registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, and cost estimation tools; appointments solution for online appointments, reminders, and referral tracking; and patient activation solution that enables providers to communicate with their patients through surveys, announcements, messaging, and health campaigns. In addition, the company's Phreesia Platform offers clinical support solution, which collects clinical intake and PRO data for approximately 25 specialties; and life sciences solution to deliver targeted and clinically relevant marketing content to patients, as well as COVID-19 product offerings for managing COVID-19 vaccine delivery and identify vaccine-hesitant patients, screening for self-reported COVID-19 risk factors, enabling contactless check-in during in-person visits, and collecting intake information during telehealth visits. It serves patients; single-specialty practices, multi-specialty groups, and health systems; and pharmaceutical, medical device, and biotechnology companies.
Steps to owning and managing CORZ, with 24-hour and historical pricing before you buy.
Bitcoin breached the $40,000 price level and may plummet lower as Russia signals a potential ban.
Cardano’s first metaverse project is available to investors now — if you can find a piece of digital land on sale. Plots sold fast despite the project’s early stage limitations.
Melania Trump launched an NFT platform — you can buy an image of her eyes.
Read our expert analysis on Vigorus and how the token will perform in the future.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
